This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bard, J. M. Articles by BIGPRO Study Group, o. b. o. t. Search for Related Content PubMed PubMed Citation Articles by Bard, J. M. Articles by BIGPRO Study Group, o. b. o. t. Related Collections Lipids Obesity Risk Factors Other diabetes Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:407.)
© 2001 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Accumulation of Triglyceride-Rich Lipoprotein in Subjects With Abdominal Obesity

The Biguanides and the Prevention of the Risk of Obesity (BIGPRO) 1 Study

J. M. Bard; M. A. Charles; I. Juhan-Vague; P. Vague; P. André; M. Safar; J. C. Fruchart; E. Eschwege; on behalf of the BIGPRO Study Group¹

From the UFR de Pharmacie et INSERM U539 (J.M.B.), Centre de Recherche en Nutrition Humaine, Nantes, France; INSERM U21-258 (M.A.C., P.A., E.E.), Villejuif, France; CJF INSERM (I.J.-V., P.V.), Laboratoire d’Hématologie, Marseille, France; INSERM U337 (M.S.), Paris, France; and INSERM U325 (J.C.F.), Lille, France.

Correspondence to Prof J.M. Bard, UFR de Pharmacie Laboratoire de Biochimie, 1 rue Gaston Veil, BP 1024, F-44035 Nantes cedex, France. E-mail Jean-Marie.bard{at}sante.univ-nantes.fr

Abstract—The present study represents a new insight into the Biguanides and the Prevention of the Risk of Obesity (BIGPRO) 1 study population at inclusion. This population, selected basically on the basis of a high waist-to-hip ratio (0.95 for men and 0.80 for women), is supposed to represent a group of patients with insulin resistance. The present study was undergone to establish whether apolipoprotein C-III (apoC-III) and apolipoprotein E (apoE) associated with apo B (apoC-III LpB and apoE LpB, respectively), considered to be markers of remnant accumulation, play a role in the hypertriglyceridemia associated with insulin resistance and whether they are related to other biological abnormalities frequently observed in this syndrome. In this population, the concentration of the markers of remnant accumulation increases with triglyceride levels. Therefore, correlation studies were realized to assess the relative effect of insulin and the markers of remnant accumulation on triglyceride plasma level. As a first attempt, a simple correlation analysis revealed that insulin is positively related to the markers of remnant accumulation only in hypertriglyceridemic patients (triglycerides 1.7 mmol/L). To assess the independent contribution of these markers, insulin, and other parameters related to the plasma triglyceride concentration, a stepwise multiple regression analysis was run. Results revealed that insulin and the markers of remnant accumulation (specifically, apoE LpB) are independent contributors to the plasma triglyceride concentration. Markers of the endothelial damage, plasminogen activator inhibitor-1, tissue plasminogen activator, and von Willebrand factor, which are often increased in the case of insulin resistance, were tested for their correlation with the markers of remnant accumulation. Plasminogen activator inhibitor-1 is positively correlated with these markers only in hypertriglyceridemic male subjects. It is concluded that increased insulin levels found in insulin resistance syndrome are associated with an increased production of triglyceride-rich lipoproteins enriched in apoC-III and apoE. The accumulation of these remnants and/or their abnormal composition in apoC-III and apoE could be an explanation for the development of hypertriglyceridemia in this syndrome.

Key Words: insulin resistance syndrome • central fat distribution • triglyceride-rich lipoproteins • apolipoproteins • lipoprotein particles

This article has been cited by other articles:

				S. Qu, D. Su, J. Altomonte, A. Kamagate, J. He, G. Perdomo, T. Tse, Y. Jiang, and H. H. Dong PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1 Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E421 - E434. [Abstract] [Full Text] [PDF]

				J. A. Moreno, F. Perez-Jimenez, C. Marin, P. Perez-Martinez, R. Moreno, P. Gomez, Y. Jimenez-Gomez, J. A. Paniagua, D. Lairon, and J. Lopez-Miranda The Apolipoprotein E Gene Promoter (-219G/T) Polymorphism Determines Insulin Sensitivity in Response to Dietary Fat in Healthy Young Adults J. Nutr., November 1, 2005; 135(11): 2535 - 2540. [Abstract] [Full Text] [PDF]

				O. Olivieri, A. Bassi, C. Stranieri, E. Trabetti, N. Martinelli, F. Pizzolo, D. Girelli, S. Friso, P. F. Pignatti, and R. Corrocher Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease J. Lipid Res., December 1, 2003; 44(12): 2374 - 2381. [Abstract] [Full Text] [PDF]

				D. C. Chan, G. F. Watts, P. H. Barrett, J. C.L. Mamo, and T. G. Redgrave Markers of Triglyceride-rich Lipoprotein Remnant Metabolism in Visceral Obesity Clin. Chem., February 1, 2002; 48(2): 278 - 283. [Abstract] [Full Text] [PDF]